Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
John Lee
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Living Beings
Physiology
Anatomy
Disorders
Sign-in to see full Profile
Network (preview)
16
Adams, Jerry
16
Griswold, Don
15
Badger, AM
15
Kumar, Sanjay
10
Young, Peter
9
Kassis, Shouki
7
Votta, Bartholomew
6
Webb, Edward
6
Boehm, Jeffrey
6
Gowen, Maxine
6
Gallagher, TF
5
Livi, George
5
ohlstein, Eliot
4
McDonnell, PC
4
McLaughlin, Megan
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of John Lee (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2003: Kumar Sanjay; Boehm Jeffrey; Lee John C
p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases.
Nature reviews. Drug discovery 2003;2(9):717-26.
-
2003: Wan Zehong; Boehm Jeffrey C; Bower Michael J; Kassis Shouki; Lee John C; Zhao Baoguang; Adams Jerry L
N-Phenyl-N-purin-6-yl ureas: the design and synthesis of p38alpha MAP kinase inhibitors.
Bioorganic & medicinal chemistry letters 2003;13(6):1191-4.
-
2002: Kumar Sanjay; Hanning Charles R; Brigham-Burke Michael R; Rieman David J; Lehr Ruth; Khandekar Sanjay; Kirkpatrick Robert B; Scott Gilbert F; Lee John C; Lynch Frank J; Gao Wentao; Gambotto Andrea; Lotze Michael T
Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production.
Cytokine 2002;18(2):61-71.
-
2002: Ju Haisong; Nerurkar Sandhya; Sauermelch Charles F; Olzinski Alan R; Mirabile Rosanna; Zimmerman Dawn; Lee John C; Adams Jerry; Sisko Joseph; Berova Marinella; Willette Robert N
Sustained activation of p38 mitogen-activated protein kinase contributes to the vascular response to injury.
The Journal of pharmacology and experimental therapeutics 2002;301(1):15-20.
-
2001: Adams J L; Boehm J C; Gallagher T F; Kassis S; Webb E F; Hall R; Sorenson M; Garigipati R; Griswold D E; Lee J C
Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity.
Bioorganic & medicinal chemistry letters 2001;11(21):2867-70.
-
2001: Kumar S; Connor J R; Dodds R A; Halsey W; Van Horn M; Mao J; Sathe G; Mui P; Agarwal P; Badger A M; Lee J C; Gowen M; Lark M W
Identification and initial characterization of 5000 expressed sequenced tags (ESTs) each from adult human normal and osteoarthritic cartilage cDNA libraries.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2001;9(7):641-53.
-
2001: Behr T M; Nerurkar S S; Nelson A H; Coatney R W; Woods T N; Sulpizio A; Chandra S; Brooks D P; Kumar S; Lee J C; Ohlstein E H; Angermann C E; Adams J L; Sisko J; Sackner-Bernstein J D; Willette R N
Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction.
Circulation 2001;104(11):1292-8.
-
2001: Kumar S; Votta B J; Rieman D J; Badger A M; Gowen M; Lee J C
IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase.
Journal of cellular physiology 2001;187(3):294-303.
-
2001: Barone F C; Irving E A; Ray A M; Lee J C; Kassis S; Kumar S; Badger A M; Legos J J; Erhardt J A; Ohlstein E H; Hunter A J; Harrison D C; Philpott K; Smith B R; Adams J L; Parsons A A
Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia.
Medicinal research reviews 2001;21(2):129-45.
-
2001: Barone F C; Irving E A; Ray A M; Lee J C; Kassis S; Kumar S; Badger A M; White R F; McVey M J; Legos J J; Erhardt J A; Nelson A H; Ohlstein E H; Hunter A J; Ward K; Smith B R; Adams J L; Parsons A A
SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.
The Journal of pharmacology and experimental therapeutics 2001;296(2):312-21.
-
2001: Adams J L; Badger A M; Kumar S; Lee J C
p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines.
Progress in medicinal chemistry 2001;38():1-60.
-
2000: Yue T L; Gu J L; Wang C; Reith A D; Lee J C; Mirabile R C; Kreutz R; Wang Y; Maleeff B; Parsons A A; Ohlstein E H
Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy.
The Journal of biological chemistry 2000;275(48):37895-901.
-
2000: Badger A M; Roshak A K; Cook M N; Newman-Tarr T M; Swift B A; Carlson K; Connor J R; Lee J C; Gowen M; Lark M W; Kumar S
Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2000;8(6):434-43.
-
2000: Underwood D C; Osborn R R; Bochnowicz S; Webb E F; Rieman D J; Lee J C; Romanic A M; Adams J L; Hay D W; Griswold D E
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.
American journal of physiology. Lung cellular and molecular physiology 2000;279(5):L895-902.
-
2000: Kassis S; Melhuish T; Annan R S; Chen S L; Lee J C; Livi G P; Creasy C L
Saccharomyces cerevisiae Yak1p protein kinase autophosphorylates on tyrosine residues and phosphorylates myelin basic protein on a C-terminal serine residue.
The Biochemical journal 2000;348 Pt 2():263-72.
-
2000: Lee J C; Kumar S; Griswold D E; Underwood D C; Votta B J; Adams J L
Inhibition of p38 MAP kinase as a therapeutic strategy.
Immunopharmacology 2000;47(2-3):185-201.
-
2000: Underwood D C; Osborn R R; Kotzer C J; Adams J L; Lee J C; Webb E F; Carpenter D C; Bochnowicz S; Thomas H C; Hay D W; Griswold D E
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
The Journal of pharmacology and experimental therapeutics 2000;293(1):281-8.
-
2000: Yue T L; Wang C; Gu J L; Ma X L; Kumar S; Lee J C; Feuerstein G Z; Thomas H; Maleeff B; Ohlstein E H
Inhibition of extracellular signal-regulated kinase enhances Ischemia/Reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart.
Circulation research 2000;86(6):692-9.
-
2000: Badger A M; Griswold D E; Kapadia R; Blake S; Swift B A; Hoffman S J; Stroup G B; Webb E; Rieman D J; Gowen M; Boehm J C; Adams J L; Lee J C
Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis.
Arthritis and rheumatism 2000;43(1):175-83.
-
1999: Kumar S; Jiang M S; Adams J L; Lee J C
Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase.
Biochemical and biophysical research communications 1999;263(3):825-31.
-
1999: Kumar S; Hand A T; Connor J R; Dodds R A; Ryan P J; Trill J J; Fisher S M; Nuttall M E; Lipshutz D B; Zou C; Hwang S M; Votta B J; James I E; Rieman D J; Gowen M; Lee J C
Identification and cloning of a connective tissue growth factor-like cDNA from human osteoblasts encoding a novel regulator of osteoblast functions.
The Journal of biological chemistry 1999;274(24):17123-31.
-
1999: Lee J C; Kassis S; Kumar S; Badger A; Adams J L
p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials.
Pharmacology & therapeutics 1999;82(2-3):389-97.
-
1999: Zhang W; Lee J C; Kumar S; Gowen M
ERK pathway mediates the activation of Cdk2 in IGF-1-induced proliferation of human osteosarcoma MG-63 cells.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1999;14(4):528-35.
-
1999: Ma X L; Kumar S; Gao F; Louden C S; Lopez B L; Christopher T A; Wang C; Lee J C; Feuerstein G Z; Yue T L
Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion.
Circulation 1999;99(13):1685-91.
-
1998: Adams J L; Boehm J C; Kassis S; Gorycki P D; Webb E F; Hall R; Sorenson M; Lee J C; Ayrton A; Griswold D E; Gallagher T F
Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes.
Bioorganic & medicinal chemistry letters 1998;8(22):3111-6.
-
1998: Gum R J; McLaughlin M M; Kumar S; Wang Z; Bower M J; Lee J C; Adams J L; Livi G P; Goldsmith E J; Young P R
Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket.
The Journal of biological chemistry 1998;273(25):15605-10.
-
1997: Kumar S; McDonnell P C; Gum R J; Hand A T; Lee J C; Young P R
Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles.
Biochemical and biophysical research communications 1997;235(3):533-8.
-
1997: Young P R; McLaughlin M M; Kumar S; Kassis S; Doyle M L; McNulty D; Gallagher T F; Fisher S; McDonnell P C; Carr S A; Huddleston M J; Seibel G; Porter T G; Livi G P; Adams J L; Lee J C
Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site.
The Journal of biological chemistry 1997;272(18):12116-21.
-
1997: Gallagher T F; Seibel G L; Kassis S; Laydon J T; Blumenthal M J; Lee J C; Lee D; Boehm J C; Fier-Thompson S M; Abt J W; Soreson M E; Smietana J M; Hall R F; Garigipati R S; Bender P E; Erhard K F; Krog A J; Hofmann G A; Sheldrake P L; McDonnell P C; Kumar S; Young P R; Adams J L
Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase.
Bioorganic & medicinal chemistry 1997;5(1):49-64.
-
1996: Badger A M; Bradbeer J N; Votta B; Lee J C; Adams J L; Griswold D E
Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function.
The Journal of pharmacology and experimental therapeutics 1996;279(3):1453-61.
-
1996: Kumar S; Orsini M J; Lee J C; McDonnell P C; Debouck C; Young P R
Activation of the HIV-1 long terminal repeat by cytokines and environmental stress requires an active CSBP/p38 MAP kinase.
The Journal of biological chemistry 1996;271(48):30864-9.
-
1996: Boehm J C; Smietana J M; Sorenson M E; Garigipati R S; Gallagher T F; Sheldrake P L; Bradbeer J; Badger A M; Laydon J T; Lee J C; Hillegass L M; Griswold D E; Breton J J; Chabot-Fletcher M C; Adams J L
1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency.
Journal of medicinal chemistry 1996;39(20):3929-37.
-
1996: Griswold D E; Hillegass L M; O'Leary-Bartus J; Lee J C; Laydon J T; Torphy T J
Evaluation of human cytokine production and effects of pharmacological agents in a heterologous system in vivo.
Journal of immunological methods 1996;195(1-2):1-5.
-
1996: McLaughlin M M; Kumar S; McDonnell P C; Van Horn S; Lee J C; Livi G P; Young P R
Identification of mitogen-activated protein (MAP) kinase-activated protein kinase-3, a novel substrate of CSBP p38 MAP kinase.
The Journal of biological chemistry 1996;271(14):8488-92.
-
1995: Kumar S; McLaughlin M M; McDonnell P C; Lee J C; Livi G P; Young P R
Human mitogen-activated protein kinase CSBP1, but not CSBP2, complements a hog1 deletion in yeast.
The Journal of biological chemistry 1995;270(49):29043-6.
-
1994: Lee J C; Laydon J T; McDonnell P C; Gallagher T F; Kumar S; Green D; McNulty D; Blumenthal M J; Heys J R; Landvatter S W
A protein kinase involved in the regulation of inflammatory cytokine biosynthesis.
Nature 1994;372(6508):739-46.
-
1994: Lee J C; Prabhakar U; Griswold D E; Dunnington D; Young P R; Badger A
Low-molecular-weight TNF biosynthesis inhibitors: strategies and prospectives.
Circulatory shock 1994;44(3):97-103.
-
1994: Prabhakar U; Lipshutz D; Bartus J O; Slivjak M J; Smith E F; Lee J C; Esser K M
Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor.
International journal of immunopharmacology 1994;16(10):805-16.
-
1993: Lee J C; Badger A M; Griswold D E; Dunnington D; Truneh A; Votta B; White J R; Young P R; Bender P E
Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors.
Annals of the New York Academy of Sciences 1993;696():149-70.
-
1993: Olivera D L; Laydon J T; Hillegass L; Badger A M; Lee J C
Effects of pyridinyl imidazole compounds on murine TNF-alpha production.
Agents and actions 1993;39 Spec No():C55-7.
-
1993: Kassis S; Prabhakar U; Lee J C
Inhibition of interleukin-1 (IL-1) and tumor necrosis factor (TNF) production by pyridinyl imidazole compounds is independent of cAMP elevating mechanisms.
Agents and actions 1993;39 Spec No():C64-6.
-
1992: Olivera D L; Esser K M; Lee J C; Greig R G; Badger A M
Beneficial effects of SK&F 105809, a novel cytokine-suppressive agent, in murine models of endotoxin shock.
Circulatory shock 1992;37(4):301-6.
-
1991: Griswold D E; Connor J R; Dalton B J; Lee J C; Simon P; Hillegass L; Sieg D J; Hanna N
Activation of the IL-1 gene in UV-irradiated mouse skin: association with inflammatory sequelae and pharmacologic intervention.
The Journal of investigative dermatology 1991;97(6):1019-23.
-
1991: Griswold D E; Marshall P J; Lee J C; Webb E F; Hillegass L M; Wartell J; Newton J; Hanna N
Pharmacology of the pyrroloimidazole, SK&F 105809--II. Antiinflammatory activity and inhibition of mediator production in vivo.
Biochemical pharmacology 1991;42(4):825-31.
-
1991: Marshall P J; Griswold D E; Breton J; Webb E F; Hillegass L M; Sarau H M; Newton J; Lee J C; Bender P E; Hanna N
Pharmacology of the pyrroloimidazole, SK&F 105809--I. Inhibition of inflammatory cytokine production and of 5-lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.
Biochemical pharmacology 1991;42(4):813-24.
-
1989: Lee J C; Votta B; Griswold D E; Hanna N
Inhibitory effect of SK&F 86002 on monocyte IL-1 production.
Agents and actions 1989;27(3-4):280-1.
-
1989: Kassis S; Lee J C; Hanna N
Effects of prostaglandins and cAMP levels on monocyte IL-1 production.
Agents and actions 1989;27(3-4):274-6.
-
1988: Lee J C; Badger A M; Johnson W J
Human non-interferon macrophage activating factor: biological and biochemical characterization.
Advances in experimental medicine and biology 1988;239():217-21.
-
1988: Lee J C; Griswold D E; Votta B; Hanna N
Inhibition of monocyte IL-1 production by the anti-inflammatory compound, SK&F 86002.
International journal of immunopharmacology 1988;10(7):835-43.
-
1987: Lee J C; Dimartino M J; Votta B J; Hanna N
Effect of auranofin treatment on aberrant splenic interleukin production in adjuvant arthritic rats.
Journal of immunology (Baltimore, Md. : 1950) 1987;139(10):3268-74.
-
1986: Lee J C; Rebar L; Young P; Ruscetti F W; Hanna N; Poste G
Identification and characterization of a human T cell line-derived lymphokine with MAF-like activity distinct from interferon-gamma.
Journal of immunology (Baltimore, Md. : 1950) 1986;136(4):1322-8.
-
1986: DiMartino M J; Lee J C; Badger A M; Muirhead K A; Mirabelli C K; Hanna N
Antiarthritic and immunoregulatory activity of spirogermanium.
The Journal of pharmacology and experimental therapeutics 1986;236(1):103-10.
-
1985: Lee J C; Rebar L; Demuth S; Hanna N
Suppressed IL-2 production and response in AA rats: role of suppressor cells and the effect of auranofin treatment.
The Journal of rheumatology 1985;12(5):885-91.
-
1985: Griswold D E; Lee J C; Poste G; Hanna N
Modulation of macrophage-lymphocyte interactions by the antiarthritic gold compound, auranofin.
The Journal of rheumatology 1985;12(3):490-7.
-
1982: Lee J C; Hapel A J; Ihle J N
Constitutive production of a unique lymphokine (IL 3) by the WEHI-3 cell line.
Journal of immunology (Baltimore, Md. : 1950) 1982;128(6):2393-8.
-
1982: Ihle J N; Rebar L; Keller J; Lee J C; Hapel A J
Interleukin 3: possible roles in the regulation of lymphocyte differentiation and growth.
Immunological reviews 1982;63():5-32.
-
1982: Ihle J N; Enjuanes L; Lee J C; Keller J
The immune response to C-type viruses and its potential role in leukemogenesis.
Current topics in microbiology and immunology 1982;101():31-49.
-
1982: Ihle J N; Lee J C
Possible immunological mechanisms in C-type viral leukemogenesis in mice.
Current topics in microbiology and immunology 1982;98():85-101.
-
1982: Hapel A J; Lee J C; Greenberger J; Ihle J N
Characteristics of IL-3 derived and IL-3 dependent lymphocyte cell lines.
Advances in experimental medicine and biology 1982;149():719-24.
-
1981: Lee J C; Ihle J N
Increased responses to lymphokines are correlated with preleukemia in mice inoculated with Moloney leukemia virus.
Proceedings of the National Academy of Sciences of the United States of America 1981;78(12):7712-6.
-
1981: Ihle J N; Lee J C; Rebar L
T cell recognition of Moloney leukemia virus proteins. III. T cell proliferative responses against gp70 are associated with the production of a lymphokine inducing 20 alpha-hydroxysteroid dehydrogenase in splenic lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1981;127(6):2565-70.
-
1981: Lee J C; Enjuanes L; Cicurel L; Ihle J N
T cell recognition of Moloney sarcoma virus proteins. II. Phenotypes of the different lymphocyte subpopulations producing and responding to blastogenic factors and their relative frequencies during tumor regression.
Journal of immunology (Baltimore, Md. : 1950) 1981;127(1):78-83.
-
1981: Hapel A J; Lee J C; Farrar W L; Ihle J N
Establishment of continuous cultures of thy1.2+, Lyt1+, 2-T cells with purified interleukin 3.
Cell 1981;25(1):179-86.
-
1981: Enjuanes L; Lee J C; Ihle J N
T cell recognition of Moloney sarcoma virus proteins during tumor regression. I. Lack of a requirement for macrophages and the role of blastogenic factors in T cell proliferation.
Journal of immunology (Baltimore, Md. : 1950) 1981;126(4):1478-84.
-
1981: Fischinger P J; Thiel H J; Ihle J N; Lee J C; Elder J H
Detection of a recombinant murine leukemia virus-related glycoprotein on virus-negative thymoma cells.
Proceedings of the National Academy of Sciences of the United States of America 1981;78(3):1920-4.
-
1981: Lee J C; Horak I; Ihle J N
Mechanisms in T cell leukemogenesis. II. T cell responses of preleukemic BALB/c mice to Moloney leukemia virus antigens.
Journal of immunology (Baltimore, Md. : 1950) 1981;126(2):715-22.
-
1981: Lee J C; Ihle J N
Chronic immune stimulation is required for Moloney leukaemia virus-induced lymphomas.
Nature 1981;289(5796):407-9.
-
1981: Horak I; Enjuanes L; Lee J C; Ihle J N
Resistance of cultures of normal T cells to infection with murine type C viruses.
Journal of virology 1981;37(1):483-7.
-
1980: Horak I; Lee J C; Enjuanes L; Ihle J N
Characterization of a unique defective type C virus associated with a Moloney leukemia virus-induced splenic T-cell lymphoma cell line.
Journal of virology 1980;36(2):299-308.
-
1980: Cicurel L; Lee J C; Enjuanes L; Ihle J N
Monoclonal antibodies to the envelope proteins of Moloney leukemia virus: characterization of recombinant viruses.
Transplantation proceedings 1980;12(3):394-7.
-
1980: Pepersack L; Lee J C; McEwan R; Ihle J N
Phenotypic heterogeneity of Moloney leukemia virus-induced T cel lymphomas.
Journal of immunology (Baltimore, Md. : 1950) 1980;124(1):279-85.
-
1980: Benade L E; Bassin R H; Ihle J N; Lee J C; Rein A
Isolation and characterization of a unique C57BL B-tropic virus.
Virology 1980;100(1):199-203.
-
1979: Lee J C; Ihle J N
Mechanisms of C-type viral leukemogenesis. I. Correlation of in vitro lymphocyte blastogenesis to viremia and leukemia.
Journal of immunology (Baltimore, Md. : 1950) 1979;123(5):2351-8.
-
1979: Enjuanes L; Lee J C; Ihle J N
Antigenic specificities of the cellular immune response of C57BL/6 mice to the Moloney leukemia/sarcoma virus complex.
Journal of immunology (Baltimore, Md. : 1950) 1979;122(2):665-74.
-
1977: Lee J C; Ihle J N
Characterization of the blastogenic and cytotoxic responses of normal mice to ecotropic C-type viral gp71.
Journal of immunology (Baltimore, Md. : 1950) 1977;118(3):928-34.
-
1977: Lee J C; Ihle J N; Huebner R
The humoral immune response of NIH Swiss and SWR/J mice to vaccination with formalinized AKR or Gross murine leukemia virus.
Proceedings of the National Academy of Sciences of the United States of America 1977;74(1):343-7.
-
1977: Ihle J N; Lee J C
The immune response of (C57BL/6 X C3H)F1 mice to the endogenous AKR-MuLV.
Medical microbiology and immunology 1977;164(1-3):207-16.
-
1976: Ihle J N; Collins J J; Lee J C; Fischinger P J; Moennig V; Schäfer W; Hanna M G; Bolognesi D P
Characterization of the immune response to the major glycoprotein (gp 71) of Friend leukemia virus. I. Response in BALB/c mice.
Virology 1976;75(1):74-87.
-
1976: Ihle J N; Collins J J; Lee J C; Fischinger P J; Pazmino N; Moennig V; Schäfer W; Hanna M G; Bolognesi D P
Characterization of the immune response to the major glycoprotein (gp71) of Friend leukemia virus. III. Influence on endogenous MuLV-mediated pathogenesis.
Virology 1976;75(1):102-12.
-
1976: Ihle J N; Lee J C; Collins J J; Fischinger P J; Pazmino N H; Moennig V; Schäfer W; Hanna M G; Bolognesi D P
Characterization of the immune response to the major glycoprotein (gp71) of Friend leukemia virus. II. Response in C57BL/6 mice.
Virology 1976;75(1):88-101.
-
1976: Lee J C; Ihle J N
Inhibition of normal mouse lymphocyte mitogen responses by xenogeneic or allogeneic antibodies to the MuLV glycoprotein gp71.
Journal of immunology (Baltimore, Md. : 1950) 1976;117(3):1033-8.
-
1976: Hanna M G; Ihle J N; Lee J C
Autogenous immunity to endogenous RNA tumor virus: humoral immune response to virus envelope antigens.
Cancer research 1976;36(2 pt 2):608-14.
-
1975: Lee J C; Ihle J N
Autogenous immunity to endogenous RNA tumor virus: reactivity of natural immune sera to antigenic determinants of several biologically distinct murine leukemia viruses.
Journal of the National Cancer Institute 1975;55(4):831-8.
-
1974: Lee J C; Hanna M G; Ihle J N; Aaronson S A
Autogenous immunity to endogenous RNA tumor virus: differential reactivities of immunoglobulins M and G to virus envelope antigens.
Journal of virology 1974;14(4):773-81.
-
1974: Lee J C; Sigel M M
A differential effect of IgM and IgG antibodies on the blastogenic response of lymphocytes to rubella virus.
Cellular immunology 1974;13(1):22-31.
Sign-in to see more
